Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters
MV Varma, AF El‐Kattan, Bo Feng et al. · Clinical Pharmacology & Therapeutics · 2016
Additional Supporting Information may be found in the online version of this article. Supplementary Table 1. Summary of victim DDIs with rifampicin as inhibitor – OATP1B1/1B3. Supplementary Table 2. Summary of victim DDIs with cyclosporine as inhibitor – OATP1B1/1B3, P-gp and BCRP. Supplementary Table 3. Summary of victim DDIs with probenecid as inhibitor – OAT1/3. Supplementary Table 4. Summary of victim DDIs with cimetidine as inhibitor – OCT2/MATEs. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Cited by 42 works. doi:10.1002/cpt.595
Authors
References
- Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
- Transporter‐Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug–Drug Interactions of Montelukast
- Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System